HOUSTON / Apr 23, 2024 / Business Wire / U.S. Physical Therapy, Inc. (NYSE: USPH), a national operator of outpatient physical therapy clinics and provider of industrial injury prevention services, announced that it will report its financial results for the first quarter ended March 31, 2024, on Tuesday, May 7, 2024, after the stock market closes, with the conference call to follow the next morning, on Wednesday, May 8, 2024.
Conference Call | Date: | Wednesday, May 8, 2024 | |
|
| Time: | 10:30 am Eastern/9:30 am Central |
|
| Dial-In Number: | (800) 267-6316 Primary or |
|
|
| (203) 518-9783 Alternate |
|
| Conference ID: | USPHQ124 |
|
| (In order to join this conference call, | |
To participate, please call in 10 minutes prior to start time. |
To listen to the live call, please go to www.usph.com and click on conference calls under the Investor Relations section. Please go to the website 15 minutes early to register, download and install any necessary audio software. If you are unable to listen live, a playback of the conference call can be accessed until August 8, 2024, at U.S. Physical Therapy’s website.
About U.S. Physical Therapy, Inc.
Founded in 1990, U.S. Physical Therapy, Inc. operates 679 outpatient physical therapy clinics in 42 states. The Company's clinics provide preventative and post-operative care for a variety of orthopedic-related disorders and sports-related injuries, treatment for neurologically-related injuries and rehabilitation of injured workers. In addition to owning and operating clinics, the Company manages 41 physical therapy facilities for unaffiliated third parties, including hospitals and physician groups. The Company also has an industrial injury prevention services business which provides onsite services for clients’ employees including injury prevention and rehabilitation, performance optimization, post-offer employment testing, functional capacity evaluations, and ergonomic assessments.
More information about U.S. Physical Therapy, Inc. is available at www.usph.com The information included on that website is not incorporated into this press release.
Last Trade: | US$68.45 |
Daily Change: | -1.16 -1.67 |
Daily Volume: | 95,413 |
Market Cap: | US$1.030B |
March 03, 2025 February 26, 2025 December 02, 2024 November 12, 2024 November 05, 2024 |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORECompass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MOREEnd of content
No more pages to load